-
Product Insights
CR Caofeidian Power Plant Phase I
CR Caofeidian Power Plant Phase I is a thermal project located in Hebei, China. The project is owned by China Resources Power Holdings Co Ltd. The project came online in 2009. Empower your strategies with our CR Caofeidian Power Plant Phase I report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Diazoxide Choline CR in Prader-Willi Syndrome (PWS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Diazoxide Choline CR in Prader-Willi Syndrome (PWS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Diazoxide Choline CR in Prader-Willi Syndrome (PWS) Drug Details:...
-
Sector Analysis
NewReconstruction Meshes Market Size by Segments, Share, Regulatory, Reimbursement, Procedures and Forecast to 2033
Reconstruction Meshes Market Size by Segments, Share, Regulatory, Reimbursement, Procedures and Forecast to 2033 is built to visualize quantitative market trends within General Surgery Devices therapeutic area. The model discusses in detail the impact of COVID-19 on Reconstruction Meshes market for the year 2020 and beyond. Reconstruction Meshes are surgically implantable woven sheets that are used to repair or support organs and other tissues. The meshes are made either from synthetic material and/or bioengineered from animal tissues. The breast reconstruction...
-
Product Insights
NewNet Present Value Model: Sanofi’s Rilzabrutinib
Empower your strategies with our Net Present Value Model: Sanofi's Rilzabrutinib report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
DoT Texas – US 81 from FM 2264 to CR 4421 – Texas
Equip yourself with the essential tools needed to make informed and profitable decisions with our DoT Texas – US 81 from FM 2264 to CR 4421 – Texas report. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Reasons to buy Acquire a...
-
Product Insights
DoT Texas – US 67 from US 385 to CR 450 – Texas
Equip yourself with the essential tools needed to make informed and profitable decisions with our DoT Texas – US 67 from US 385 to CR 450 – Texas report. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Reasons to buy Acquire a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ondansetron Hydrochloride CR in Diarrhea
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ondansetron Hydrochloride CR in Diarrhea Drug Details: Ondansetron hydrochloride (RHB-102, Bekinda) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Diazoxide Choline Cr in Obesity
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Diazoxide Choline Cr in Obesity report and make more profitable business decisions. How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nitazoxanide CR in Rhinovirus Infections
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Nitazoxanide CR in Rhinovirus InfectionsDrug Details: Nitazoxanide is under development for the treatment of coronavirus disease...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CR-9114 in Influenzavirus A Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CR-9114 in Influenzavirus A Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.CR-9114 in Influenzavirus A InfectionsDrug Details:CR-9114 is under development for the protection...